Open AccessEglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
Author(s) -
Shuijie Li,
Javier Rodríguez,
Wenyu Li,
Petra Bullova,
Stuart M. Fell,
Olga Surova,
Isabelle Westerlund,
Danijal Topcic,
Maria Bergsland,
Adam Stenman,
Jonas Muhr,
Monica Nistér,
Johan Holmberg,
C. Christofer Juhlin,
Catharina Larsson,
Alex von Kriegsheim,
William G. Kaelin,
Susanne Schlisio
Publication year - 2019
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1900748116
Subject(s) - mutant , wild type , cancer research , biology , mutation , kinase , mapk/erk pathway , programmed cell death , phosphorylation , microbiology and biotechnology , apoptosis , genetics , gene
Significance Different mutations of the von Hippel–Lindau (VHL) tumor suppressor gene cause different subtypes of VHL hereditary cancer syndrome. Dysregulation of VHL’s canonical substrate, HIFα, cannot fully explain the complex genotype/phenotype manifestation within VHL disease. We describe an oxygen-sensitive function of VHL that regulates hydroxylated BIM-EL protein stability. Type 2C VHL mutants, which cause pheochromocytoma and paraganglioma (PCC/PGL) despite repressing HIFα, destabilize BIM-EL. Other genetic mutations linked to PCC/PGL, similar to loss of BIM-EL, protect from apoptosis upon nerve growth factor withdrawal. Dysregulation of BIM-EL might therefore contribute to the pathogenesis of VHL-related PCC/PGL. Loss of BIM-EL expression can lead to chemotherapy resistance in other VHL-related neoplasms and renders clear cell renal cell carcinoma cells insensitive to cisplatin.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom